{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:59:56Z","timestamp":1785387596132,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Chronic immune thrombocytopenia (ITP) is characterized by persistent thrombocytopenia and bleeding risk, and a subset of patients remains refractory or relapses despite multiple lines of therapy. Avatrombopag is an oral thrombopoietin receptor agonist approved for adults with chronic ITP with insufficient response to prior treatment. We descrixbe a real-world single-center experience with avatrombopag in Oman.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective case series of consecutive adults with chronic primary ITP treated with avatrombopag at a tertiary care center in Muscat, Oman. Patients initiated avatrombopag between September 2023 and June 2025 and were followed through October 2025. Platelet counts, treatment patterns, transfusion requirements, corticosteroid use, rescue therapies, and adverse drug reactions (ADRs) were abstracted from electronic medical records.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twelve heavily pretreated patients were included, with a median baseline platelet count of 14.5 \u00d7 10\n 9<\/jats:sup>\n \/L (IQR 4.8\u201328.8). Eleven patients (91.7%) started avatrombopag at 20 mg once daily, and one patient (8.3%) started at 20 mg on alternate days; 66.7% required subsequent dose adjustment. Overall, 75.0% achieved platelet counts \u2265 50 \u00d7 10\n 9<\/jats:sup>\n \/L at least once during follow-up, with a median platelet count of 160 \u00d7 10\n 9<\/jats:sup>\n \/L at month 3 and 98 \u00d7 10\n 9<\/jats:sup>\n \/L at the most recent assessment. Transfusion burden improved in 60% of patients with high baseline transfusion requirements. Steroid-sparing was observed in 83.3, and 66.7% were steroid-free during follow-up. ADRs occurred in 33.3% (primarily body pain and rash); no hepatotoxicity or treatment discontinuation due to ADRs was documented.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In chronic, heavily pretreated ITP, avatrombopag was associated with clinically meaningful platelet responses, substantial steroid-sparing, and an acceptable tolerability profile.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1850341","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:42Z","timestamp":1785385302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman"],"prefix":"10.3389","volume":"13","author":[{"given":"Nashwa","family":"Al-Sharji","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sultan Qaboos University Hospital, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hematology and Bone Marrow Transplant Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen","family":"Al-Zadjali","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hematology and Bone Marrow Transplant Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Huneini","sequence":"additional","affiliation":[{"name":"Department of Adult Hematology, National Hematology and Bone Marrow Transplant Center, University Medical City","place":["Muscat, Oman"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP).","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/ejh.14395","article-title":"Avatrombopag for the treatment of immune thrombocytopenia.","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia.","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1055\/a-2336-1062","article-title":"Epidemiology, treatment patterns, and cost analysis of immune thrombocytopenia in Spain between 2014 and 2020: a population-based study.","volume":"8","author":"Gonz\u00e1lez-L\u00f3pez","year":"2024","journal-title":"TH Open."},{"key":"B5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life.","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia.","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B7","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia.","volume":"76","author":"Provan","year":"2022","journal-title":"EBioMedicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia.","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1182\/hematology.2025000720","article-title":"Refractory ITP: revisiting definitions, diagnostics, and management paradigms.","volume":"2025","author":"Panch","year":"2025","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00277-022-04786-y","article-title":"Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.","volume":"101","author":"Vianelli","year":"2022","journal-title":"Ann Hematol."},{"key":"B11","unstructured":"Search Orphan Drug Designations and Approvals [Internet].\n \n 2011"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets."},{"key":"B15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12185-025-04001-4","article-title":"A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.","volume":"122","author":"Yamaguchi","year":"2025","journal-title":"Int J Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"102158","DOI":"10.1016\/j.rpth.2023.102158","article-title":"Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China.","volume":"7","author":"Mei","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"B17","doi-asserted-by":"publisher","first-page":"20406207231179856","DOI":"10.1177\/20406207231179856","article-title":"Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study.","volume":"14","author":"Oladapo","year":"2023","journal-title":"Ther Adv Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/TCRM.S251672","article-title":"Avatrombopag for the treatment of adult patients with chronic immune thrombocytopenia (cITP): focus on patient selection and perspectives.","volume":"18","author":"Tsykunova","year":"2022","journal-title":"Ther Clin Risk Manag."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","article-title":"Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis.","volume":"38","author":"Wojciechowski","year":"2021","journal-title":"Adv Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis of randomized controlled trials.","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed Rep."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1850341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:21:42Z","timestamp":1785385302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1850341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1850341"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1850341","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1850341"}}